#Chronic Kidney Disease Market Size

[blog-site-for-market-research]

Unveiling Trends Shaping Chronic Kidney Disease Market

Market Overview –

The Chronic Kidney Disease (CKD) Market is experiencing significant growth globally due to the rising prevalence of CKD and related risk factors such as diabetes and hypertension. CKD, characterized by a gradual loss of kidney function over time, poses a substantial health burden worldwide. Factors such as aging populations, unhealthy lifestyles, and genetic predisposition contribute to the increasing incidence of CKD.

The Chronic Kidney Disease market is undergoing notable developments, particularly in patients with renal kidney disease. Hemianopsia, characterized by partial blindness in one half of the visual field, can occur as a complication of renal kidney disease. Research into effective management and treatment options is driving advancements in this niche market to improve quality of life for affected individuals.

The market encompasses various treatment options, including medications, dialysis, and kidney transplantation, aimed at managing symptoms and slowing disease progression. Additionally, advancements in diagnostic techniques and therapies drive market growth by improving early detection and management strategies.

However, challenges such as high treatment costs, limited access to healthcare services, and the complexity of managing CKD patients' care hinder market expansion. Despite these challenges, the CKD market presents opportunities for innovation and collaboration among healthcare stakeholders to improve diagnosis, treatment, and management approaches, ultimately enhancing patient outcomes and quality of life.

In 2022, the market for chronic kidney disease was estimated to be worth USD 65.88 billion. The market for chronic kidney disease is expected to increase at a compound annual growth rate (CAGR) of 5.5% between 2023 and 2030, from USD 69.44 billion in 2023 to USD 101.2 billion.

Segmentation –

By diagnosis, the chronic kidney disease market is segmented into blood test, urine test, imaging test, and kidney biopsy.

By treatment, the global chronic kidney disease market has been segmented into drugs, dialysis, and kidney transplant. The drugs segment is further sub-segmented into ace inhibitors, angiotensin-ii receptor blockers, calcium channel blockers, beta-blockers, and erythropoiesis-stimulating agents.

By indication, the chronic kidney disease market is segmented into Type 1 or Type 2 diabetes, high blood pressure, polycystic kidney disease, and others.

By end-user, the global chronic kidney disease market has been segmented into hospitals and clinics, diagnostic centers, and others.

Regional Analysis –

The chronic kidney disease (CKD) market's regional analysis reflects disparities in healthcare access, risk factors, and treatment options. In developed regions like North America and Europe, high prevalence rates of diabetes and hypertension contribute to a significant CKD burden. Advanced healthcare infrastructure allows for early detection and management, driving market growth for CKD treatments. In contrast, developing regions such as Asia-Pacific, Latin America, and Africa face challenges in CKD management due to limited access to healthcare and diagnostic services. However, increasing awareness of CKD risk factors and government initiatives to improve healthcare infrastructure are fueling market growth in these regions. Market players must address regional disparities by offering affordable treatment options, raising awareness, and collaborating with local healthcare stakeholders to improve CKD management globally.

Key Players –

Chronic Kidney Disease companies include Abbott, Siemens, Beckman Coulter, F. Hoffmann-La Roche Ltd, ACON Laboratories, Inc, Nova Biomedical, ARKRAY, AstraZeneca, GlaxoSmithKline Plc, and Bayer AG.

Related Reports –

Meningitis Diagnosis and Treatment

Endodontic Devices

Fertility Drug and Surgery

Opioids

For more information visit at MarketResearchFuture

[heathcareforallworld]

Medical Erythropoietin Injection Market: Trends and Opportunities Through 2032

Introduction

Erythropoietin (EPO) injections are a critical treatment for patients suffering from anemia, particularly those with chronic kidney disease (CKD), cancer-related anemia, and those undergoing dialysis. EPO stimulates red blood cell production, reducing the need for blood transfusions and improving patient quality of life. As the demand for effective anemia treatments rises, the medical erythropoietin injection market is experiencing steady growth. This article explores key trends, market drivers, challenges, and future growth opportunities in the erythropoietin injection market.

Medical Erythropoietin Injection Market Size was estimated at 19.32 (USD Billion) in 2023. The Medical Erythropoietin Injection Market Industry is expected to grow from 21.22(USD Billion) in 2024 to 45.01 (USD Billion) by 2032. The Medical Erythropoietin Injection Market CAGR (growth rate) is expected to be around 9.86% during the forecast period (2025 - 2032).

Key Market Drivers

Rising Prevalence of Chronic Diseases: One of the primary drivers of the erythropoietin injection market is the growing number of patients diagnosed with chronic diseases such as CKD, cancer, and HIV. These conditions often result in anemia, which necessitates the use of erythropoietin injections to manage red blood cell levels effectively. According to the World Health Organization (WHO), over 10% of the global population is affected by chronic kidney disease, underscoring the increasing demand for anemia treatments.

Aging Population: The global aging population is also contributing to the growth of the erythropoietin injection market. As people age, they are more likely to develop chronic conditions such as CKD, cardiovascular diseases, and cancer, which can result in anemia. The elderly population, in particular, represents a significant portion of erythropoietin users as they often require long-term management of anemia-related disorders.

Advances in Biosimilars: The development and approval of biosimilar erythropoietin injections have significantly impacted the market. These biosimilars provide more affordable treatment options, increasing accessibility for patients and healthcare providers. With regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) approving several biosimilars for erythropoietin, the market is expected to witness greater competition and reduced treatment costs.

Increasing Dialysis Procedures: Dialysis patients frequently suffer from anemia due to decreased erythropoietin production by the kidneys. With a rise in the number of patients undergoing dialysis, the demand for erythropoietin injections is steadily increasing. This trend is expected to continue, given the rising prevalence of kidney disease globally.

Challenges in the Market

High Treatment Costs: Despite the availability of biosimilars, the high cost of erythropoietin injections remains a significant challenge, particularly in developing regions where access to healthcare is limited. The cost of these treatments often makes them inaccessible to low-income populations, leading to a disparity in treatment availability across different geographic regions.

Side Effects and Regulatory Concerns: Erythropoietin injections, while effective, are associated with several side effects, including high blood pressure, increased risk of blood clots, and stroke. These concerns have led to stringent regulatory oversight by bodies like the FDA, limiting the use of erythropoietin in certain patient populations. Additionally, concerns about overuse in sports for performance enhancement (doping) have prompted tighter regulations.

Market Competition: The introduction of biosimilars has intensified competition within the market, forcing leading players to adjust their pricing strategies. While competition can drive innovation, it can also lead to price pressures on original manufacturers of erythropoietin, impacting their revenue streams.

Growth Opportunities

Emerging Markets in Asia-Pacific: The Asia-Pacific region is anticipated to witness significant growth in the erythropoietin injection market, driven by rising healthcare expenditure, increasing awareness about anemia management, and a growing number of dialysis patients. Countries like China and India, with their large populations and rising prevalence of chronic diseases, present substantial opportunities for market expansion.

Increasing Focus on Biosimilars: The development of biosimilar erythropoietin injections represents a major opportunity for the market. As biosimilars become more widely accepted and approved by regulatory bodies, their affordability and accessibility will improve, potentially boosting market growth in both developed and developing regions.

Technological Advancements: Ongoing research into improving erythropoietin formulations and delivery methods, such as long-acting versions or subcutaneous administration, is expected to drive market growth. Innovations that reduce the frequency of injections or minimize side effects will likely attract more patients to erythropoietin-based therapies.

Conclusion

The medical erythropoietin injection market is poised for steady growth, driven by the rising prevalence of anemia-related conditions, an aging population, and advancements in biosimilar development. However, challenges such as high treatment costs and regulatory concerns must be addressed to ensure broader accessibility. As healthcare systems evolve and technological advancements continue, the future of the erythropoietin market looks promising, particularly in emerging regions.

[deshpandeisha]

Understanding Nephritis: Types, Causes, and Symptoms

The global nephritis market size reached USD 1.03 Billion in 2022 and is expected to register a revenue CAGR of 8.4% during the forecast period, according to the latest analysis by Emergen Research. Growing Chronic Kidney Disease (CKD) prevalence is a major factor driving the market's revenue growth. Growing developments in molecular imaging-related technologies to detect renal inflammation is a key driver of revenue growth. In addition, research & developments into the creation of Artificial Intelligence (AI)-induced inflammation detection platforms to treat nephritis is expected to increase their adoption rate given the significant prevalence of nephritis across the globe. The development of novel technologies is made possible by the rising research activities carried out by numerous institutions around the world. These technologies effectiveness makes it easier for them to enter the market.

Nephritis Market added by Emergen Research offers a comprehensive analysis of the recent advancements in the Nephritis industry and trends driving the growth of the market. It is an investigative study covering analysis of market drivers, restraints, challenges, threats, and growth prospects in the global Nephritis market. The global Nephritis market report is a methodical research of the Nephritis market done by extensive primary and secondary research. The fundamental purpose of the Nephritis market report is to offer an accurate and strategic analysis of the Nephritis business sphere.

Get Download Pdf Sample Copy of this Report@ https://www.emergenresearch.com/request-sample/1736

Competitive Terrain:

The global Nephritis industry is highly consolidated owing to the presence of renowned companies operating across several international and local segments of the market. These players dominate the industry in terms of their strong geographical reach and a large number of production facilities. The companies are intensely competitive against one another and excel in their individual technological capabilities, as well as product development, innovation, and product pricing strategies.

The leading market contenders listed in the report are:

Aurinia Pharmaceuticals, Hoffmann-La Roche, AstraZeneca, Boehringer Ingelheim, Novartis, Janssen Research & Development, BeiGene, Suzhou Suncadia Biopharmaceuticals Co., Ltd

Key market aspects studied in the report:

Market Scope: The report explains the scope of various commercial possibilities in the global Nephritis market over the upcoming years. The estimated revenue build-up over the forecast years has been included in the report. The report analyzes the key market segments and sub-segments and provides deep insights into the market to assist readers with the formulation of lucrative strategies for business expansion.

Competitive Outlook: The leading companies operating in the Nephritis market have been enumerated in this report. This section of the report lays emphasis on the geographical reach and production facilities of these companies. To get ahead of their rivals, the leading players are focusing more on offering products at competitive prices, according to our analysts.

Report Objective: The primary objective of this report is to provide the manufacturers, distributors, suppliers, and buyers engaged in this sector with access to a deeper and improved understanding of the global Nephritis market.

Emergen Research is Offering Limited Time Discount (Grab a Copy at Discounted Price Now)@ https://www.emergenresearch.com/request-discount/1736

Market Segmentations of the Nephritis Market

This market is segmented based on Types, Applications, and Regions. The growth of each segment provides accurate forecasts related to production and sales by Types and Applications, in terms of volume and value for the period between 2022 and 2030. This analysis can help readers looking to expand their business by targeting emerging and niche markets. Market share data is given on both global and regional levels. Regions covered in the report are North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Research analysts assess the market positions of the leading competitors and provide competitive analysis for each company. For this study, this report segments the global Nephritis market on the basis of product, application, and region:

Segments Covered in this report are:

Stage Outlook (Revenue, USD Billion; 2019-2032)

Stage I

Stage II

Others

Medication Outlook (Revenue, USD Billion; 2019-2032)

Immunosuppressive drugs

Corticosteroids  

Others

Regional Outlook (Revenue, USD Billion; 2019–2032)

North America

U.S.

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Spain

Benelux

Rest of Europe

Asia Pacific

China

India

Japan

South Korea

Rest of APAC

Latin America

Brazil

Rest of LATAM

Middle East & Africa

Saudi Arabia

UAE

South Africa

Turkey

Rest of MEA

Browse Full Report Description + Research Methodology + Table of Content + Infographics@ https://www.emergenresearch.com/industry-report/nephritis-market

Major Geographies Analyzed in the Report:

North America (U.S., Canada)

Europe (U.K., Italy, Germany, France, Rest of EU)

Asia Pacific (India, Japan, China, South Korea, Australia, Rest of APAC)

Latin America (Chile, Brazil, Argentina, Rest of Latin America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)

ToC of the report:

Chapter 1: Market overview and scope

Chapter 2: Market outlook

Chapter 3: Impact analysis of COVID-19 pandemic

Chapter 4: Competitive Landscape

Chapter 5: Drivers, Constraints, Opportunities, Limitations

Chapter 6: Key manufacturers of the industry

Chapter 7: Regional analysis

Chapter 8: Market segmentation based on type applications

Chapter 9: Current and Future Trends

Request Customization as per your specific requirement@ https://www.emergenresearch.com/request-for-customization/1736

About Us:

Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyse consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Contact Us:

Eric Lee

Corporate Sales Specialist

Emergen Research | Web: www.emergenresearch.com

Direct Line: +1 (604) 757-9756

E-mail: sales@emergenresearch.com

Visit for More Insights: https://www.emergenresearch.com/insights

Explore Our Custom Intelligence services | Growth Consulting Services

Trending Titles: Geocell Market | Pancreatic Cancer Treatment Market

Latest Report:  Ceramic Tiles Market | Life Science Analytics Market

[credenceresearchdotblog]

The Organ Transplantation Market is projected to grow from USD 7965 million in 2024 to an estimated USD 13818.94 million by 2032, with a compound annual growth rate (CAGR) of 7.13% from 2024 to 2032.The organ transplantation market is a rapidly evolving sector within the global healthcare industry, driven by advancements in medical technology, an increasing prevalence of chronic diseases, and a growing awareness of organ donation. Organ transplantation, the process of surgically transferring a healthy organ from a donor to a patient in need, plays a vital role in saving lives and improving the quality of life for individuals suffering from organ failure. Despite its lifesaving potential, the sector faces significant challenges, such as a limited supply of organs, high transplantation costs, and ethical concerns. This article explores the current state of the organ transplantation market, key drivers of growth, and the challenges that need to be addressed.

Browse the full report at https://www.credenceresearch.com/report/organ-transplantation-market

Market Overview

The global organ transplantation market has shown significant growth in recent years. In 2022, it was valued at approximately USD 13.6 billion, with projections suggesting it could reach USD 18.5 billion by 2030, growing at a compound annual growth rate (CAGR) of around 4.5%. This expansion is driven by factors such as an aging global population, rising incidences of chronic diseases, including diabetes, cardiovascular diseases, and kidney disorders, and improved success rates of organ transplantation procedures due to technological advancements.

North America dominates the global organ transplantation market, accounting for the largest share due to well-established healthcare infrastructure, high awareness about organ donation, and robust government support. The United States, in particular, has a well-organized organ procurement and transplantation network, with significant contributions from private and public health organizations. Europe follows closely behind, while the Asia-Pacific region is expected to witness the fastest growth in the coming years due to increasing healthcare expenditure, rising organ failure cases, and government initiatives promoting organ donation.

Key Drivers of Market Growth

1. Rising Organ Failure Cases: A growing number of patients suffering from end-stage organ failure is one of the primary drivers of the organ transplantation market. The rising incidence of chronic diseases such as diabetes, hypertension, and cardiovascular diseases is increasing the demand for kidney, liver, heart, and lung transplants. For example, kidney transplants remain the most commonly performed organ transplantation procedure due to the global rise in chronic kidney disease (CKD) cases.

2. Technological Advancements: Continuous advancements in surgical techniques, immunosuppressive drugs, and organ preservation methods have significantly improved the success rates of organ transplantation. Innovations such as 3D printing of organs, tissue engineering, and the use of artificial organs are also expected to revolutionize the market in the near future. These advancements not only enhance the success rate of transplants but also reduce the risks of organ rejection.

3. Increasing Awareness and Government Initiatives: Over the past decade, public awareness about organ donation has increased significantly, driven by government campaigns, non-profit organizations, and media. Several countries have introduced policies to encourage organ donation, such as opt-out systems, where citizens are presumed to be organ donors unless they explicitly choose otherwise. These initiatives aim to address the chronic shortage of donor organs, which remains a critical bottleneck in the transplantation process.

Major Challenges

Despite the market’s growth, several challenges hinder its full potential:

1. Shortage of Donor Organs: One of the most pressing issues in the organ transplantation market is the severe shortage of donor organs. While the demand for organs continues to grow, the supply has not kept pace. This has resulted in long waiting lists, with many patients dying before receiving a suitable organ. Efforts to increase deceased and living organ donations have seen limited success in most regions.

2. High Cost of Transplantation: Organ transplantation is an expensive procedure, often involving long-term hospital stays, costly immunosuppressive medications, and post-operative care. This limits access to transplantation for many patients, especially in low- and middle-income countries where healthcare systems may lack the resources to support such complex procedures.

3. Ethical and Legal Issues: The organ transplantation market is fraught with ethical concerns, particularly regarding the source of donor organs. Illegal organ trade and unethical practices, such as organ trafficking, continue to be a problem in certain parts of the world. This raises serious legal and moral questions about how to ensure a fair and transparent system of organ donation and allocation.

Future Prospects

Looking ahead, the future of the organ transplantation market is promising, with several developments on the horizon. Bioprinting of organs using 3D printing technology, advancements in xenotransplantation (transplanting organs from animals to humans), and the use of stem cells for organ regeneration are expected to address some of the major challenges the market currently faces.

Furthermore, continued efforts to increase awareness and streamline the organ donation process, alongside policy reforms, could help bridge the gap between supply and demand. Countries with high demand for organ transplants are likely to focus on improving organ donation rates through public health campaigns, donor registration drives, and changes to legal frameworks.

Key Player Analysis:

Accord Healthcare GmbH (Spain)

ASTELLAS PHARMA, Inc. (Japan)

Bio-Med PVT. Ltd. (US)

GlaxoSmithKline Plc. (UK),

Hoffmann-La Roche Ltd. (Switzerland)

Novartis International AG (Switzerland)

Organ OX Limited (UK)

Pfizer, Inc. (US)

Preservation Solutions, Inc. (US)

SANOFI (France)

Terumo Medical Corporation (US)

Trans Medic, Inc. (US)

Transonic (US)

Transplant Biomedical (UK)

VELOXIS Pharmaceuticals A/S (Denmark)

Segmentation:

By Product Type,

Immunosuppressive drugs,

Organ preservation solutions,

Transplant diagnostics.

By Transplant Type,

Kidney,

Liver,

Heart,

Lung,

Pancreas,

By Treatment Type,

Transplantation procedures

Organ preservation techniques.

By Application,

Therapeutic

Research applications.

By End User,

Hospitals,

Transplant centers,

Research laboratories.

By Region

North America

The U.S

Canada

Mexico

Europe

Germany

France

The U.K.

Italy

Spain

Rest of Europe

Asia Pacific

China

Japan

India

South Korea

South-east Asia

Rest of Asia Pacific

Latin America

Brazil

Argentina

Rest of Latin America

Middle East & Africa

GCC Countries

South Africa

Rest of Middle East and Africa

Browse the full report at https://www.credenceresearch.com/report/organ-transplantation-market

About Us:

Credence Research is committed to employee well-being and productivity. Following the COVID-19 pandemic, we have implemented a permanent work-from-home policy for all employees.

Contact:

Credence Research

Please contact us at +91 6232 49 3207

Email: sales@credenceresearch.com

Website: www.credenceresearch.com

[tamanna31]

Blood Screening Market 2023- Business Planning Research and Resources, Revenue, and Forecasts 2030

Blood Screening Market Size & Trends

The global blood screening market size was valued at USD 2.76 billion in 2022 and is anticipated to grow at a compound annual growth rate (CAGR) of 11.7% from 2023 to 2030. 

Blood screening is a process in which donated blood is screened for infectious diseases such as HBV, HCV, HIV1, and HIV2. The high growth of this market is attributed to rising blood donations, an increase in the incidence of infectious diseases, and government initiatives. According to World Health Organization (WHO), 118.54 million blood donations are collected yearly. In the U.S., 6.8 million individuals donate blood annually, and 13.6 million units of red blood cells and whole blood are collected annually.

Gather more insights about the market drivers, restrains and growth of the Blood Screening Market

The market is primarily driven by the rise in the rate of disorders such as HIV, diphtheria, measles and chronic diseases such as hemophilia, cancer, and other blood-related disorders. Blood-based diagnostics are used to diagnose a wide range of diseases, including infectious diseases, cancer, and cardiovascular diseases. Serology tests detect the presence of antibodies to a specific disease-causing organism. These tests diagnose various infectious diseases, including HIV, hepatitis B, and syphilis. Molecular tests detect the presence of DNA or RNA from a specific disease-causing organism. These tests are more sensitive than serology tests and can be used to diagnose diseases at an earlier stage. Biochemical tests measure the levels of certain substances in the blood. These tests can diagnose a wide range of diseases, including diabetes, kidney disease, and liver disease.

The COVID-19 pandemic had a significant impact on the market. Although respiratory droplets are the primary means of COVID-19 virus transmission, research has shown that viral RNA may be discovered in blood samples, supporting blood screening for COVID-19 identification, hence driving the market significantly. 

Blood Screening Market Segmentation

Grand View Research has segmented the global blood screening market based on technology, product, and region:

Technology Outlook (Revenue, USD Million, 2018 - 2030)

Nucleic Acid Amplification Test (NAT)

ELISA

Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA)

Next Generation Sequencing

Western Blotting

Product Outlook (Revenue, USD Million, 2018 - 2030)

Reagent

Instrument

Regional Outlook (Revenue, USD Million, 2018 - 2030)

North America

US

Canada

Europe

UK

Germany

France

Italy

Spain

Sweden

Norway

Denmark

Asia Pacific

Japan

China

India

Australia

Thailand

South Korea

Latin America

Brazil

Mexico

Argentina

Middle East and Africa

Saudi Arabia

South Africa

UAE

Kuwait

Browse through Grand View Research's Medical Devices Industry Research Reports.

The global embolic protection devices market size was valued at USD 612.9 million in 2023 and is projected to grow at a CAGR of 8.7% from 2024 to 2030. 

The global covered stent market size was estimated at USD 1.13 billion in 2023 and is projected to grow at a CAGR of 4.1% from 2024 to 2030. 

Key Companies & Market Share Insights

Product launches, approvals, strategic acquisitions, and innovations are just a few of the important business strategies used by market participants to maintain and grow their global reach.

For instance, in March 2023, Abbott received U.S Food and Drug Administration (FDA) clearance for a laboratory traumatic brain injury blood test, the first commercially available lab-based test for the assessment of mild traumatic brain injuries (TBIs), commonly referred to as concussions, which will be made widely available to hospitals across the U.S. This test, which is powered by Abbott’s Alinity i laboratory tool, will enable clinicians to evaluate individuals with mild traumatic brain injuries in a timely manner.

Furthermore, in May 2023, Siemens Healthcare introduced Atellica HEMA 570 and 580 next-generation hematology analyzers, which have user-friendly interfaces and can be connected to multiple analyzers to remove workflow barriers and provide high throughput time.

Key Blood Screening Companies:

Abbott

Danaher Corporation (Beckman Coulter)

Becton Dickinson and Company

Bio-Rad Laboratories, Inc.

Hoffman-La Roche Ltd.

Grifols, S.A.

Ortho-Clinical Diagnostics, Inc.

Siemens Healthcare GmbH

Thermo Fisher Scientific, Inc.

SOFINA s.a (Biomerieux)

Order a free sample PDF of the Blood Screening Market Intelligence Study, published by Grand View Research. 

[industrynewsupdates]

Enteral Feeding Devices Market Key Drivers and Emerging Trends 2024-2030

The global enteral feeding devices market size was valued at USD 4.3 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 5.0% from 2024 to 2030. 

Growing geriatric population has resulted in increased incidences of diabetes, severe pancreatitis, and other gastrointestinal diseases, which aids market growth. Adoption of the “Feed Early Enteral Diet Adequately for Maximum Effect” (FEED ME) protocol in surgical trauma ICUs in the U.S. enables subsidies on these devices. Technological advancements such as the introduction of tri-funnel replacement G-tubes and J-tubes with reverse balloon designs are also expected to aid in growth during the forecast period.

Gather more insights about the market drivers, restrains and growth of the Enteral Feeding Devices Market

Numerous NCBI studies suggest that people over 65 years pose a higher risk of developing chronic illnesses including Parkinson’s and nervous system disorders. The global population aged 60 years and older is expected to increase from around 1 billion in 2020 to about 1.4 billion in 2030 and is expected to double by 2050 to reach around 2.1 billion. The number of elderly patients with critical illnesses has increased significantly over the past few years. The risk of malnutrition and frailty among the geriatric population with comorbidities, such as stroke, depression, and dementia, is much higher, mainly owing to various age-related changes in body composition and muscle mass. This results in a reduced ability to perform Activities of Daily Living (ADLs), thereby increasing the risk of falls or injuries.

Enteral Feeding Devices Market Segmentation

Grand View Research, Inc. has segmented the global enteral feeding devices market report based on product, age group, indication, end-use, and region:

Product Outlook (Revenue, USD Million, 2018 - 2030)

• Giving Set

• Enteral Feeding Pump

• Percutaneous Endoscopic Gastrostomy Device

• Low Profile Gastrostomy Device

• Nasogastric Tube

• Gastrostomy Tube

Age Group Outlook (Revenue, USD Million, 2018 - 2030)

• Adults 

• Pediatrics

Indication Outlook (Revenue, USD Million, 2018 - 2030)

• Alzheimer’s

• Nutrition Deficiency

• Cancer Care

• Diabetes

• Chronic Kidney Diseases

• Orphan Diseases

• Dysphagia

• Pain Management

• Malabsorption/GI Disorder/Diarrhea

• Others

End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Hospitals

o Cardiology

o Neurology

o Critical Care (ICU)

o Oncology

o Others

• Home Care

Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

o U.S.

o Canada

• Europe

o U.K.

o Germany

o France

o Spain `          

o Italy

o Russia

o Sweden

o Norway

o Denmark

• Asia Pacific

o China

o Japan

o India

o South Korea

o Australia

o Thailand

o Singapore

• Latin America

o Brazil

o Mexico

o Argentina

• MEA

o South Africa

o Saudi Arabia

o UAE

o Kuwait

Browse through Grand View Research's Medical Devices Industry Research Reports.

• The global surgical drills market size was estimated at USD 1.27 billion in 2023 and is projected to grow at a CAGR of 5.5% from 2024 to 2030.

• The global ophthalmic ultrasound devices market size was valued at USD 590.9 million in 2023 and is projected to grow at a CAGR of 5.7% from 2024 to 2030.

Key Companies & Market Share Insights

The market players are focusing on product development, new technological advancements, and other initiatives to strengthen their market position.

Key Enteral Feeding Devices Companies:

• Conmed Corporation

• C.R.Bard

• Cook Medical

• Boston Scientific Corporation

• Moog Inc.

• Fresenius Kabi AG

• Danone Medical Nutrition

• Kimberly-Clark

• Abbott Nutrition

• B Braun Melsungen AG

• Avanos Medical, Inc.

• Cardinal Health

• Applied Medical Technology, Inc.

• Vygon India

• Fidmi Medical

• ALCOR Scientific

• Amsino International, Inc.

Recent Developments

• In September 2023, Cardinal Health launched Kangaroo OMNI enteral feeding pump, intended to give patients undergoing enteral feeding more options to suit their individual needs over the course of their enteral feeding journey.

• In August 2023, Cardinal Health launched its next-generation NTrainerTM System 2.0, a medical device intended to shorten the length of stay in the neonatal intensive care unit (NICU) for premature and newborn infants by assisting them in developing the oral coordination skills necessary for the transition to independent feeding more quickly. The NTrainerTM System gives parents confidence in their newborns' progress and potential for success after discharge by giving clinicians the objective data they need to monitor an infant's development of pre-feeding skills through real-time assessment technology.

Order a free sample PDF of the Enteral Feeding Devices Market Intelligence Study, published by Grand View Research.

[market-insider]

SGLT2 Inhibitors Market Overview: Extensive Evaluation of Market Size, Share, and Growth Opportunities

The global SGLT2 inhibitors market size is anticipated to reach USD 29.43 billion by 2030 and is expected to expand at a CAGR of 7.71% during the forecast period, according to a new report by Grand View Research, Inc. The recommendations and supportive guidelines from major health organizations, such as the American Diabetes Association (ADA), the European Association of for the Study of Diabetes (EASD), the European Society of Cardiology (ESC), and others have endorsed sodium-glucose cotransporter-2 (SGLT2) inhibitors for them beyond glucose control. For instance, in August 2023, the European Society of Cardiology (ESC) has issued a focused update to their heart failure guidelines, integrating findings from nearly a dozen new clinical trials since 2021, such as EMPEROR-Preserved, DELIVER, STRONG-HF, and IRONMAN. Released at the ESC Congress 2023, the updated guidelines introduce new recommendations for the use of SGLT2 inhibitors in treating patients with heart failure with mildly reduced ejection fraction (HFmrEF).

In addition, the growing number of patients needing dialysis over the next few years showcased high demand of medicines such as SGLT2 inhibitors for treatment of CKD patients. In November 2023, the National Institute for Health and Care Excellence (NICE) has issued draft guidance recommending the use of empagliflozin, an SGLT2 inhibitor, for patients with chronic kidney disease (CKD). Empagliflozin has demonstrated efficacy in slowing the progression to kidney failure and reducing the risk of heart attacks and strokes. NICE recommends making this treatment available to patients across all stages of CKD. Such recommendations from drug regulatory agencies are expected to boost demand for drugs during the forecast period.

The elder adults are more prone to type 2 diabetes and heart failure, conditions where drugs have shown substantial benefits. This demographic shift increases the demand for effective treatments such as SGLT2 inhibitors. SGLT2 inhibitors are beneficial in reducing cardiovascular and renal risks, which are particularly prevalent in the elderly. This advantage makes these medications a preferred choice for older patients. According to the World Health Organization (WHO), in 2022, around 1.4 billion people were aged 60 years and over, which was raised from 1 billion in 2020. In addition, WHO estimates that the elderly population is expected to reach 2.1 billion. Thus, rising geriatric population is expected to boost demand for SGLT2 inhibitors worldwide and drive market growth.

Increasing awareness of diabetes and significance of SGLT2 inhibitors in treatment among both patients and healthcare providers contribute to higher prescription rates. For instance, in 2021, the WHO launched initiative “Global Diabetes Compact” to raise awareness and improve patient access to diabetic medicine including SGLT2 inhibitors and insulin. Such initiatives are expected to boost adoption of SGLT2 inhibitors and open new opportunities in the market over the forecast period.

For More Details or Sample Copy please visit link @: SGLT2 Inhibitors Market Report

SGLT2 Inhibitors Market Report Highlights

Jardiance (empagliflozin) segment dominated the market in 2023 and is anticipated to grow significantly over the forecast period. This growth is attributed due to increasing prevalence of diabetes, CKD, and cardiovascular conditions and high drug demand for treatment

Type 2 diabetes segment dominated the market in 2023. This dominance is attributed due to rising incidence of diabetes, increasing geriatric population, and increased prescription rate of drug

Hospital pharmacies segment dominated the market in 2023. This dominance is attributed due to increasing number hospitalization of diabetes, CKD, and heart failure patients for diagnosis and treatment

North America dominated the market owing to factors such as advanced healthcare infrastructure, rising prevalence of target diseases, and favorable regulatory environment

SGLT2 Inhibitors Market Segmentation

Grand View Research has segmented the global SGLT2 inhibitors market on the basis of drug, indication, distribution channel, and region.

Gain deeper insights on the market and receive your free copy with TOC now @: SGLT2 Inhibitors Market Report

[blog-site-for-market-research]

Chronic Kidney Disease Market Report, Analysis, Growth Forecasts, Statistics Report

Overview:

In 2022, the market for chronic kidney disease was estimated to be worth USD 65.88 billion. The chronic kidney disease market is expected to increase from USD 69.44 billion in 2023 to USD 101.2 billion by 2030, with a compound annual growth rate (CAGR) of 5.5% during the forecast period (2023- 2030). Market Research Future (MRFR) reveals various factors that can impact the market outcome in the coming years, like an increasing number of biopsy procedures, the inclusion of new technologies in the healthcare sector, market competition to develop better products and edge out rivals, hike in research investment, and others. However, in some cases, the high cost associated with procedures can deter the market from having good growth. 

Segmentation:

The global report on the chronic kidney disease market outlook has been studied by MRFR experts after getting it segmented on the basis of indication, diagnosis, treatment, and end-user. This recording of segments is backed by a close study of various factors and demographic challenges that would help the market in developing strategies with better possible impacts. 

By diagnosis, the report contains details of the chronic kidney disease market with segmentation into urine tests, imaging tests, blood tests, and kidney biopsy. The imaging test segment is getting traction for its ability to provide certainty regarding the process.

By treatment, the market report has been segmented into dialysis, drugs, and kidney transplant. The drugs segment has been segmented into angiotensin-ii receptor blockers, ace inhibitors, beta-blockers, calcium channel blockers, and erythropoiesis-stimulating agents.

By indication, the report on the chronic kidney disease market includes segments like high blood pressure, polycystic kidney disease, Type 1 or Type 2 diabetes, and others. Growing number of diabetes patient is spurring the demand for type 1 or type 2 diabetes segment.

By end-user, the global market report on chronic kidney disease market report has been segmented into diagnostic centers, hospitals and clinics, and others. The hospitals and clinics segment has been getting thrust from the market for its ability to address the disease with better infrastructure is higher than other parts. 

Regional Analysis:

North America has the chance to lead the market as the expenditure for the healthcare sector is high in the region. This is primarily due to the superlative healthcare setup and improved reimbursement policies that help more patients in going for a check-up. On the other hand, the presence of countries like the US and Canada are expected to boost the regional market. In Europe, market growth would get backed by countries like the UK, Italy, France, Germany, and others. In the Asia Pacific region, growth would be backed by emerging nations and their revamped healthcare industry.

Competitive Analysis:

The global market for chronic kidney disease market depends on the strategic moves made by companies like Beckman Coulter, Abbott, Siemens, Sysmex, ACON Laboratories, Inc., F. Hoffmann-La Roche Ltd, ARKRAY, OPTI Medical, URIT Medical, Nova Biomedical, Teva Pharmaceutical Industries Ltd., 77 Elektronika, Randox Laboratories, Pfizer Inc., AbbVie Inc., Amgen Inc., AstraZeneca Plc, GlaxoSmithKline Plc, F. Hoffmann-La Roche Ltd., Sanofi S.A., and Kissei Pharmaceutical Co. Ltd. These companies and their latest proceedings have been tracked by MRFR for a better understanding of the market growth impacts and maps. 

About Market Research Future:

Market Research Future (MRFR) is a global market research company that takes pride in its services, offering a complete and accurate analysis with regard to diverse markets and consumers worldwide. Market Research Future has the distinguished objective of providing the optimal quality research and granular research to clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help answer your most important questions.

Contact Us:

Market Research Future (Part of Wantstats Research and Media Private Limited)

99 Hudson Street, 5Th Floor

New York, NY 10013

United States of America

+1 628 258 0071 (US)

+44 2035 002 764 (UK)

Email: sales@marketresearchfuture.com

Website: https://www.marketresearchfuture.com

[heathcareforallworld]

Exploring the Growth Drivers of the Potassium Sparing Diuretic Market Through 2032

Introduction

The Potassium Sparing Diuretic Market is a vital segment within the broader diuretics market, known for its essential role in managing conditions like hypertension and heart failure. Unlike other diuretics, potassium-sparing diuretics prevent the loss of potassium, a critical electrolyte, during urine production. As the global prevalence of cardiovascular diseases rises, the demand for these diuretics is expected to grow significantly. This article provides an in-depth analysis of the Potassium Sparing Diuretic Market, focusing on its size, share, industry trends, and forecasts up to 2032.

Market Overview

Potassium-sparing diuretics, such as spironolactone, eplerenone, triamterene, and amiloride, are increasingly prescribed due to their unique ability to retain potassium while effectively managing fluid retention and hypertension. The global Potassium Sparing Diuretic Market is witnessing steady growth, driven by the rising incidence of cardiovascular diseases, kidney disorders, and other chronic conditions that require diuretic therapy.

Market Size and Share

Potassium Sparing Diuretic Market Size was estimated at 1.59 (USD Billion) in 2023. The Potassium Sparing Diuretic Market Industry is expected to grow from 1.67(USD Billion) in 2024 to 2.5 (USD Billion) by 2032. The Potassium Sparing Diuretic Market CAGR (growth rate) is expected to be around 5.16% during the forecast period (2024 - 2032). The region's dominance is attributed to the high prevalence of cardiovascular diseases, advanced healthcare infrastructure, and increasing awareness about the benefits of potassium-sparing diuretics. Europe follows closely, driven by similar factors, while the Asia-Pacific region is anticipated to witness the fastest growth due to its expanding population, rising healthcare expenditure, and improving access to healthcare services.

Key Industry Trends

Increasing Prevalence of Cardiovascular Diseases: Cardiovascular diseases remain the leading cause of mortality worldwide, driving the demand for effective treatments, including potassium-sparing diuretics. The growing burden of hypertension and heart failure, in particular, is a significant factor contributing to the market's expansion. As more patients are diagnosed with these conditions, the need for potassium-sparing diuretics is expected to rise.

Technological Advancements and Drug Development: The pharmaceutical industry is witnessing continuous advancements in drug development, leading to the introduction of more effective and safer potassium-sparing diuretics. Improved formulations and combination therapies are becoming increasingly popular, offering better patient outcomes and reducing the risk of side effects. Additionally, ongoing research into novel therapeutic applications for potassium-sparing diuretics is expected to create new growth opportunities in the market.

Rising Awareness and Patient Education: There is a growing awareness among patients and healthcare providers about the importance of maintaining electrolyte balance during diuretic therapy. Potassium-sparing diuretics are increasingly being recommended as a safer alternative to traditional diuretics, particularly for patients at risk of hypokalemia (low potassium levels). This trend is expected to continue, driving the adoption of potassium-sparing diuretics in clinical practice.

Increasing Healthcare Expenditure: The rise in global healthcare expenditure, particularly in emerging economies, is expected to boost the demand for potassium-sparing diuretics. Governments and private organizations are investing heavily in healthcare infrastructure, improving access to diagnostic and treatment services. As a result, more patients are receiving appropriate care, including diuretic therapy, which is expected to drive market growth.

Growing Geriatric Population: The aging global population is another significant factor contributing to the growth of the Potassium Sparing Diuretic Market. Older adults are more susceptible to conditions like hypertension, heart failure, and kidney disorders, all of which may require diuretic therapy. As the geriatric population continues to grow, the demand for potassium-sparing diuretics is expected to increase.

Market Forecast and Future Outlook

Looking ahead, the Potassium Sparing Diuretic Market is poised for steady growth through 2032. The market's expansion will be fueled by the rising prevalence of cardiovascular diseases, technological advancements in drug development, and increasing awareness about the benefits of potassium-sparing diuretics. Additionally, the growing geriatric population and rising healthcare expenditure will further drive demand.

The Asia-Pacific region is expected to emerge as a key growth market, driven by factors such as rapid urbanization, an expanding middle class, and increasing investment in healthcare infrastructure. Meanwhile, North America and Europe will continue to dominate the market, benefiting from advanced healthcare systems and high disease prevalence rates.

Challenges and Opportunities

Despite the positive outlook, the Potassium Sparing Diuretic Market faces several challenges. These include the potential side effects of diuretics, such as hyperkalemia (high potassium levels), which can limit their use in certain patient populations. Additionally, the availability of alternative treatments and the high cost of newer formulations may pose challenges to market growth.

However, these challenges also present opportunities for innovation. Pharmaceutical companies are investing in research and development to create safer, more effective diuretics with fewer side effects. Additionally, the growing emphasis on personalized medicine and targeted therapies is expected to open new avenues for market growth.

Conclusion

The Potassium Sparing Diuretic Market is set to experience steady growth over the next decade, driven by the rising prevalence of cardiovascular diseases, technological advancements, and increasing healthcare expenditure. As the market evolves, opportunities for innovation and expansion will continue to emerge, making potassium-sparing diuretics a critical component of modern healthcare.

[deshpandeisha]

Introduction to Continuous Renal Replacement Therapy: Understanding the Basics

The global continuous renal replacement therapy (CRRT) market size was USD 1.41 Billion in 2022 and is expected to register a rapid revenue CAGR of 7.8% during the forecast period. The continuous renal replacement therapy (CRRT) market is a rapidly growing sector of the medical industry. CRRT is a process used to treat patients with acute kidney injury (AKI) or chronic kidney disease (CKD) by removing waste products and excess fluids from the blood. The therapy is continuous and performed over an extended period of time, providing a gentler and more effective treatment option than traditional dialysis. According to the National Kidney Foundation, CKD affects an estimated 37 million people in the United States, and AKI affects up to 20% of hospitalized patients.

One of the key drivers of the CRRT market is the increasing prevalence of kidney diseases. The National Kidney Foundation estimates that approximately 90% of people with kidney disease are unaware they have it. This lack of awareness means that many people may not receive proper treatment until their kidney function has already declined significantly. As a result, the demand for effective treatments like CRRT is expected to increase as more people are diagnosed with kidney diseases.

However, there are also some restraints that could hinder the growth of the CRRT market. One major restraint is the high cost of the therapy. CRRT is a complex and expensive process that requires specialized equipment and highly trained medical professionals. This can make the therapy inaccessible to some patients who cannot afford the high cost of treatment.

Get Download Pdf Sample Copy of this Report@ https://www.emergenresearch.com/request-sample/1856

Competitive Terrain:

The global Continuous Renal Replacement Therapy industry is highly consolidated owing to the presence of renowned companies operating across several international and local segments of the market. These players dominate the industry in terms of their strong geographical reach and a large number of production facilities. The companies are intensely competitive against one another and excel in their individual technological capabilities, as well as product development, innovation, and product pricing strategies.

The leading market contenders listed in the report are:

Baxter International Inc., Asahi Kasei Medical Co., Ltd., Fresenius Medical Care AG & Co. KGaA, Medtronic plc, B. Braun SE, Nipro Corporation, Informed SA, Toray Medical Co. Ltd, Medical Components Inc., and Nikkiso Co., Ltd

Key market aspects studied in the report:

Market Scope: The report explains the scope of various commercial possibilities in the global Continuous Renal Replacement Therapy market over the upcoming years. The estimated revenue build-up over the forecast years has been included in the report. The report analyzes the key market segments and sub-segments and provides deep insights into the market to assist readers with the formulation of lucrative strategies for business expansion.

Competitive Outlook: The leading companies operating in the Continuous Renal Replacement Therapy market have been enumerated in this report. This section of the report lays emphasis on the geographical reach and production facilities of these companies. To get ahead of their rivals, the leading players are focusing more on offering products at competitive prices, according to our analysts.

Report Objective: The primary objective of this report is to provide the manufacturers, distributors, suppliers, and buyers engaged in this sector with access to a deeper and improved understanding of the global Continuous Renal Replacement Therapy market.

Emergen Research is Offering Limited Time Discount (Grab a Copy at Discounted Price Now)@ https://www.emergenresearch.com/request-discount/1856

Market Segmentations of the Continuous Renal Replacement Therapy Market

This market is segmented based on Types, Applications, and Regions. The growth of each segment provides accurate forecasts related to production and sales by Types and Applications, in terms of volume and value for the period between 2022 and 2030. This analysis can help readers looking to expand their business by targeting emerging and niche markets. Market share data is given on both global and regional levels. Regions covered in the report are North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Research analysts assess the market positions of the leading competitors and provide competitive analysis for each company. For this study, this report segments the global Continuous Renal Replacement Therapy market on the basis of product, application, and region:

Segments Covered in this report are:

Product Outlook (Revenue, USD Billion; 2019-2032)

Dialysate and Replacement Fluids

Disposable

System

Modality Outlook (Revenue, USD Billion; 2019-2032)

Slow Continuous Ultra-Filtration (SCUF)

Continuous Venovenous Hemofiltration (CVVH)

Continuous Venovenous Hemodialysis (CVVHD)

Continuous Venovenous Hemodiafiltration (CVVHDF)

End-Use Outlook (Revenue, USD Billion; 2019-2032)

Hospitals and Clinics

Ambulatory Surgical Centers (ASCs)

Others

Browse Full Report Description + Research Methodology + Table of Content + Infographics@ https://www.emergenresearch.com/industry-report/continuous-renal-replacement-therapy-market

Major Geographies Analyzed in the Report:

North America (U.S., Canada)

Europe (U.K., Italy, Germany, France, Rest of EU)

Asia Pacific (India, Japan, China, South Korea, Australia, Rest of APAC)

Latin America (Chile, Brazil, Argentina, Rest of Latin America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)

ToC of the report:

Chapter 1: Market overview and scope

Chapter 2: Market outlook

Chapter 3: Impact analysis of COVID-19 pandemic

Chapter 4: Competitive Landscape

Chapter 5: Drivers, Constraints, Opportunities, Limitations

Chapter 6: Key manufacturers of the industry

Chapter 7: Regional analysis

Chapter 8: Market segmentation based on type applications

Chapter 9: Current and Future Trends

Request Customization as per your specific requirement@ https://www.emergenresearch.com/request-for-customization/1856

[credenceresearchdotblog]

The Erythropoietin (EPO) drug Market is poised for substantial growth, with its market size projected to expand from USD 11,728.5 million in 2024 to USD 24,205.87 million by 2032, reflecting a compound annual growth rate (CAGR) of 9.48%.The global erythropoietin (EPO) drugs market has experienced significant growth in recent years, driven by an increasing prevalence of anemia, particularly among patients with chronic kidney disease (CKD), cancer, and HIV. Erythropoietin, a glycoprotein hormone produced by the kidneys, plays a crucial role in the production of red blood cells (erythropoiesis). The synthetic forms of erythropoietin, known as erythropoiesis-stimulating agents (ESAs), are commonly used to treat anemia by stimulating the bone marrow to produce more red blood cells.

Browse the full report at https://www.credenceresearch.com/report/erythropoietin-drugs-market

Market Dynamics

The erythropoietin drugs market is primarily driven by the rising incidence of chronic diseases such as CKD and cancer. Anemia is a common complication in these diseases, leading to a growing demand for EPO drugs. According to the World Health Organization (WHO), anemia affects approximately 1.62 billion people globally, with iron deficiency anemia being the most prevalent type. This high prevalence, coupled with the increasing number of patients undergoing dialysis, chemotherapy, and antiretroviral therapy, is fueling the demand for EPO drugs.

The market is further bolstered by the growing geriatric population, which is more susceptible to chronic diseases and anemia. Additionally, advancements in biotechnology have led to the development of newer, more effective EPO formulations, enhancing treatment outcomes and expanding the market.

Regional Analysis

The erythropoietin drugs market is geographically segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.

- North America: This region dominates the global market due to the high prevalence of CKD, well-established healthcare infrastructure, and the presence of major pharmaceutical companies. The U.S. is the largest market within this region, driven by a high rate of dialysis procedures and an aging population. - Europe: The market in Europe is also significant, with countries like Germany, the UK, and France leading due to their advanced healthcare systems and the widespread adoption of biosimilars.

- Asia-Pacific: This region is expected to witness the highest growth rate during the forecast period, attributed to a large patient population, increasing healthcare spending, and growing awareness about anemia management.

- Latin America and the Middle East & Africa: These regions are gradually emerging as potential markets due to improving healthcare infrastructure and increasing access to medical treatments.

Challenges and Opportunities

Despite the positive growth outlook, the erythropoietin drugs market faces several challenges. The high cost of biologics, side effects associated with EPO drugs, and stringent regulatory requirements are some of the key barriers to market growth. Additionally, the emergence of biosimilars poses competition to established biologics, potentially leading to price wars and reduced profit margins for manufacturers.

However, the market also presents significant opportunities. The development of next-generation EPO drugs with improved efficacy and safety profiles, coupled with the expanding applications of these drugs beyond anemia, could drive future growth. Moreover, the increasing focus on personalized medicine and targeted therapies is expected to open new avenues in the erythropoietin drugs market.

Key Player Analysis:

Amgen Inc.

Johnson & Johnson

F. Hoffmann-La Roche Ltd.

Pfizer Inc.

Novartis AG

Biocon Limited

Teva Pharmaceutical Industries Ltd.

Dr. Reddy’s Laboratories Ltd.

LG Life Sciences Ltd.

Wockhardt Ltd.

Segmentation:

by Drug Type 

Biologics

Biosimilars

by Product Type

Epoetin-alfa

Epoetin-beta

Darbepoetin-alfa

Others

by Application

Haematology

Kidney Disorder

Cancer

Others

by End User

Hospitals

Homecare

Specialty Clinics

Others

Browse the full report at https://www.credenceresearch.com/report/erythropoietin-drugs-market

About Us:

Credence Research is committed to employee well-being and productivity. Following the COVID-19 pandemic, we have implemented a permanent work-from-home policy for all employees.

Contact:

Credence Research

Please contact us at +91 6232 49 3207

Email: sales@credenceresearch.com

Website: www.credenceresearch.com

[industrynewsupdates]

Blood Screening Market Analysis, Opportunities And Forecast Report 2024-2030

The global blood screening market size was valued at USD 2.76 billion in 2022 and is anticipated to grow at a compound annual growth rate (CAGR) of 11.7% from 2023 to 2030. 

Blood screening is a process in which donated blood is screened for infectious diseases such as HBV, HCV, HIV1, and HIV2. The high growth of this market is attributed to rising blood donations, an increase in the incidence of infectious diseases, and government initiatives. According to World Health Organization (WHO), 118.54 million blood donations are collected yearly. In the U.S., 6.8 million individuals donate blood annually, and 13.6 million units of red blood cells and whole blood are collected annually.

Gather more insights about the market drivers, restrains and growth of the Blood Screening Market

The market is primarily driven by the rise in the rate of disorders such as HIV, diphtheria, measles and chronic diseases such as hemophilia, cancer, and other blood-related disorders. Blood-based diagnostics are used to diagnose a wide range of diseases, including infectious diseases, cancer, and cardiovascular diseases. Serology tests detect the presence of antibodies to a specific disease-causing organism. These tests diagnose various infectious diseases, including HIV, hepatitis B, and syphilis. Molecular tests detect the presence of DNA or RNA from a specific disease-causing organism. These tests are more sensitive than serology tests and can be used to diagnose diseases at an earlier stage. Biochemical tests measure the levels of certain substances in the blood. These tests can diagnose a wide range of diseases, including diabetes, kidney disease, and liver disease.

The COVID-19 pandemic had a significant impact on the market. Although respiratory droplets are the primary means of COVID-19 virus transmission, research has shown that viral RNA may be discovered in blood samples, supporting blood screening for COVID-19 identification, hence driving the market significantly. 

Blood Screening Market Segmentation

Grand View Research has segmented the global blood screening market based on technology, product, and region:

Technology Outlook (Revenue, USD Million, 2018 - 2030)

• Nucleic Acid Amplification Test (NAT)

• ELISA

• Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA)

• Next Generation Sequencing

• Western Blotting

Product Outlook (Revenue, USD Million, 2018 - 2030)

• Reagent

• Instrument

Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

o U.S.

o Canada

• Europe

o UK

o Germany

o France

o Italy

o Spain

o Sweden

o Norway

o Denmark

• Asia Pacific

o Japan

o China

o India

o Australia

o Thailand

o South Korea

• Latin America

o Brazil

o Mexico

o Argentina

• Middle East and Africa

o Saudi Arabia

o South Africa

o UAE

o Kuwait

Browse through Grand View Research's Medical Devices Industry Research Reports.

• The global embolic protection devices market size was valued at USD 612.9 million in 2023 and is projected to grow at a CAGR of 8.7% from 2024 to 2030. 

• The global covered stent market size was estimated at USD 1.13 billion in 2023 and is projected to grow at a CAGR of 4.1% from 2024 to 2030. 

Key Companies & Market Share Insights

Product launches, approvals, strategic acquisitions, and innovations are just a few of the important business strategies used by market participants to maintain and grow their global reach.

For instance, in March 2023, Abbott received U.S Food and Drug Administration (FDA) clearance for a laboratory traumatic brain injury blood test, the first commercially available lab-based test for the assessment of mild traumatic brain injuries (TBIs), commonly referred to as concussions, which will be made widely available to hospitals across the U.S. This test, which is powered by Abbott’s Alinity i laboratory tool, will enable clinicians to evaluate individuals with mild traumatic brain injuries in a timely manner.

Furthermore, in May 2023, Siemens Healthcare introduced Atellica HEMA 570 and 580 next-generation hematology analyzers, which have user-friendly interfaces and can be connected to multiple analyzers to remove workflow barriers and provide high throughput time.

Key Blood Screening Companies:

• Abbott

• Danaher Corporation (Beckman Coulter)

• Becton Dickinson and Company

• Bio-Rad Laboratories, Inc.

• Hoffman-La Roche Ltd.

• Grifols, S.A.

• Ortho-Clinical Diagnostics, Inc.

• Siemens Healthcare GmbH

• Thermo Fisher Scientific, Inc.

• SOFINA s.a (Biomerieux)

Order a free sample PDF of the Blood Screening Market Intelligence Study, published by Grand View Research.